| Title |
How are we treating our systemic patients with primary Sjögren syndrome? Analysis of 1120 patients
|
|---|---|
| Published in |
International Immunopharmacology, April 2015
|
| DOI | 10.1016/j.intimp.2015.03.027 |
| Pubmed ID | |
| Authors |
H. Gheitasi, B. Kostov, R. Solans, G. Fraile, C. Suárez-Cuervo, A. Casanovas, F.J. Rascón, R. Qanneta, R. Pérez-Alvarez, M. Ripoll, M. Akasbi, B. Pinilla, J.A. Bosch, J. Nava-Mateos, B. Díaz-López, M.L. Morera-Morales, S. Retamozo, M. Ramos-Casals, P. Brito-Zerón, Autoimmune Diseases Study Group on behalf of the SS Study Group |
| Abstract |
To describe how systemic disease is treated in a large cohort of Spanish patients with primary Sjögren syndrome (pSS) in daily practice, focusing on the adequacy of therapies for the level of systemic activity measured by ESSDAI score. By December 2014, our database included 1120 consecutive patients who fulfilled the 2002 classification criteria for SS. Therapeutic schedules were classified into 4 categories: no systemic therapies, hydroxychloroquine (HCQ) and/or low dose glucocorticoids (GCS) (<20mg/day), high dose GCS (>20mg/day) and use of second-line therapies (immunosuppressive agents, intravenous immunoglobulins [IVIG] and/or rituximab [RTX]). There were 1048 (94%) females and 72 (6%) males, with a mean age at diagnosis of 54 years. The main drug-based therapeutic approaches for systemic pSS during follow-up were HCQ in 282 (25%) patients, GCS in 475 (42%, at doses >20mg/day in 255-23%), immunosuppressive agents in 148 (13%), IVIG in 25 (2%) and RTX in 35 (3%) patients. HCQ was associated with a lower risk of death (adjusted HR of 0.57, 95% 0.34-0.95). We classified 16 (7%) of the 255 patients treated with >20mg GCS and 21/148 (14%) treated with immunosuppressive agents, patients as inadequately treated, mainly associated with articular involvement of low/moderate activity. The management of pSS should be organ-specific, using low dose GCS in patients with moderate systemic activity, limiting the use of high dose GCS and second-line therapies to refractory or potentially severe scenarios. The use of systemic therapies for dryness, chronic pain or fatigue is not warranted. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 76 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 1% |
| Spain | 1 | 1% |
| Unknown | 74 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 10 | 13% |
| Student > Ph. D. Student | 10 | 13% |
| Student > Master | 10 | 13% |
| Researcher | 8 | 11% |
| Student > Bachelor | 6 | 8% |
| Other | 14 | 18% |
| Unknown | 18 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 39 | 51% |
| Psychology | 3 | 4% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Immunology and Microbiology | 2 | 3% |
| Agricultural and Biological Sciences | 1 | 1% |
| Other | 4 | 5% |
| Unknown | 24 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 June 2015.
All research outputs
#19,945,185
of 25,374,917 outputs
Outputs from International Immunopharmacology
#2,653
of 4,480 outputs
Outputs of similar age
#194,000
of 279,689 outputs
Outputs of similar age from International Immunopharmacology
#32
of 88 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,480 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.3. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,689 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 88 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 55% of its contemporaries.